H U Group HoldingsTSE:4544 +1.44%68 EBITDA Margin % is 10.66% as of Mar. 2026, which is 2% below its 10-year median of 10.92. GuruFocus rates TSE:4544 with a GF Score™ of 68/100 and a GF Value™ of 円2,771.74 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, H U Group Holdings ranks better than 61.27% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. H U Group Holdings's EBITDA for the
three
months ended in Mar. 2026 was 円6,465 Mil. H U Group Holdings's Revenue for the
three
months ended in Mar. 2026 was 円60,633 Mil. Therefore, H U Group Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 10.66%.
H U Group Holdings (TSE:4544) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
H U Group Holdings EBITDA Margin % Related Terms
H U Group Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for H U Group Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4544 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, H U Group Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H U Group Holdings EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, H U Group Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where H U Group Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H U Group Holdings (TSE:4544) has a EBITDA Margin % of 10.66% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on H U Group Holdings and its competitors. This is near median its historical median of 10.92. Over the past decade, H U Group Holdings' EBITDA Margin % has ranged from 1.48 to 20.64. According to the industry distribution chart, H U Group Holdings ranks #79 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 38.7%.
Is H U Group Holdings' EBITDA Margin % too high?
H U Group Holdings' current EBITDA Margin % of 10.66% is near median its 10-year median of 10.92. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 20.64. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. H U Group Holdings' value of 10.66% is 105% above this industry median. Based on the distribution chart, H U Group Holdings ranks #79 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, H U Group Holdings has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does H U Group Holdings' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, H U Group Holdings ranks #79 out of 204 companies for EBITDA Margin %. This puts H U Group Holdings in the upper half of its industry. The industry median EBITDA Margin % is 5.20. H U Group Holdings' value of 10.66% is 105% above this benchmark. Historically, H U Group Holdings' own EBITDA Margin % has ranged from 1.48 to 20.64 over the past decade. While the company's 10-year median is 10.92 vs. the industry median of 5.20, H U Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H U Group Holdings's current EBITDA Margin % of 10.66% is 105% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on H U Group Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H U Group Holdings's current EBITDA Margin % is 10.66%, which is near median its own 10-year median of 10.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H U Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, H U Group Holdings (TSE:4544) is currently considered Modestly Overvalued. The stock's GF Value™ is 円2,771.74, compared to a current price of 円3,244.00 — trading 17% above its estimated fair value. The current EBITDA Margin % is 10.66%, which is near median its 10-year median of 10.92 and 105% above the Medical Diagnostics & Research industry median of 5.20. H U Group Holdings' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For H U Group Holdings (TSE:4544), the current EBITDA Margin % is 10.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H U Group Holdings (TSE:4544) Overvalued in 2026?
Based on GuruFocus' analysis, H U Group Holdings stock appears to be overvalued.
The current stock price of 円3,244.00 is trading 17% above its estimated GF Value™ of 円2,771.74.
GuruFocus considers H U Group Holdings to be Modestly Overvalued.
Key valuation signals for TSE:4544:
EBITDA Margin %: 10.66% (near median its 10-year median of 10.92)
GF Value™: 円2,771.74 vs. price of 円3,244.00 (17% above fair value)
Industry Position: 105% above the Medical Diagnostics & Research median (#79 of 204)
No single metric tells the full story. See the TSE:4544 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
H U Group Holdings Inc operates in the healthcare field, focusing on clinical laboratory testing and reagents. The company is engaged in four main businesses. The Clinical Laboratory Testing Business receives samples taken from patients at medical institutions to test for the disease and confirm the condition of the patient's health; In Vitro Diagnostics develops, manufactures, and sells testing reagents and equipment inside and outside Japan; Sterilization & Related Services Business provides a range of medical-related services including sterilization; and Emerging New Business & Others is a new business for future growth.
68GF Score
Get the complete analysis for TSE:4544
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4544 has been successfully added to your 
